▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / VTRS

VTRS — Viatris Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1792044 ·
Last close
$17.24
Market Cap
$20.08B
52W High
$17.68
52W Low
$14.45
ADV30
9,860,819
Next earnings
2026-08-06
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,517,000,000 1,157,200,000 -20,200,000 176,400,000 36,834,600,000 1,804,200,000 22,176,900,000
Dec 2025 3,703,600,000 1,147,900,000 -157,500,000 -340,100,000 37,193,100,000 1,322,400,000 22,481,800,000
Sep 2025 3,759,900,000 1,371,500,000 234,500,000 -128,200,000 37,920,400,000 975,300,000 22,702,800,000
Jun 2025 3,582,100,000 1,332,900,000 185,400,000 -4,600,000 38,411,500,000 566,400,000 22,841,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,315,900,000
Investing CF
$-427,700,000
Financing CF
$-1,293,900,000
CapEx
$-465,100,000
Dividends Paid
$-561,200,000
Buybacks
$-500,500,000
EPS Diluted TTM
$-2.96
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-388,300,000
Inventory
$3,999,200,000
Receivables
$3,347,100,000
ST Investments
$190,600,000
EBIT TTM
$-3,193,700,000
Pretax Income TTM
$-3,665,000,000
Interest Exp TTM
$471,300,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$14,562,599,936
EBITDA
$4,125,199,872
Free Cash Flow
$2,238,337,536
Enterprise Value
$32,333,268,992
Total Cash
$2,400,199,936
Total Debt
$14,609,999,872
Shares Out
1,164,552,654
Trailing EPS
$-0.30
Book Value
$12.59
ROE
-2.0%
ROA
2.3%
Div Yield
2.78%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 14,299,900,000 253,500,000 -3,514,900,000 37,193,100,000 22,481,800,000 — 2,315,900,000
Dec 2024 14,739,300,000 710,300,000 -634,200,000 41,500,900,000 22,865,400,000 — 2,302,900,000
Dec 2023 15,426,900,000 1,563,400,000 54,700,000 47,685,500,000 27,218,100,000 — 2,900,000,000
Dec 2022 16,262,700,000 1,655,700,000 2,078,600,000 50,022,200,000 28,949,900,000 — 2,999,000,000

TTM Snapshot

Revenues TTM
$16,307,900,000
NetIncome TTM
$1,092,200,000
OpCashFlow TTM
$0
Assets (Latest)
$41,500,900,000
Forward EPS
$2.63

Max Pain — expiry 2026-08-21

max pain strike: $17.00 · spot: $17.24 · call oi: 8,961 · put oi: 25,324
Expected Move to 2026-08-21: ±$1.68 (9.72%) — implied range $15.56 – $18.91 · ATM straddle on $17.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GMAB GENMAB A/S $17.72B $28.87 —
INSM INSMED Inc $23.18B $106.92 —
GNMSF GENMAB A/S $16.85B $274.50 —
ASND Ascendis Pharma A/S $16.65B $253.86 —
BBIO BridgeBio Pharma, Inc. $16.46B $84.02 —

News headlines (Yahoo Finance, 1h cache)

3 Healthcare Stocks We Keep Off Our Radar
2026-07-24 16:33 · Yahoo
Trump Proposes 200% Generic Drug Tariffs, Sandoz Shares Drop 4.2%
2026-07-22 19:56 · Yahoo
Viatris’ Quarterly Earnings Preview: What You Need to Know
2026-07-22 10:45 · Yahoo
3 Unpopular Stocks We’re Skeptical Of
2026-07-20 11:27 · Yahoo
Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.
2026-07-17 19:49 · Yahoo
VTRS or DHR: Which Is the Better Value Stock Right Now?
2026-07-09 15:40 · Yahoo
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
2026-07-09 14:31 · Yahoo
Should Value Investors Buy Viatris (VTRS) Stock?
2026-07-09 13:40 · Yahoo
3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now
2026-07-07 17:19 · Yahoo
Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?
2026-07-06 09:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →